In: Obesity

VI-0521 not checked

VIVUS LLC

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pediatric Obesity, Childhood Obesity, Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight, Blood Pressure
Main trialPhase 4
“The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.”In the company’s words, NCT02714062 on ClinicalTrials.gov
Other names
Qsymia · Phentermine and topiramate · Phentermine/Topiramate

Other drugs for Blood Pressure

All 158 drugs for Blood Pressure

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 4Completed Oct 2016 A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
Phase 4Completed 16 Apr 2021 A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
Phase 4Completed 11 Apr 2023 A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow VI-0521

Following is part of Solo: you see every change to VI-0521 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in